+49.9%
XLE vs GSK
+14.9%
+34.9%
-15.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.7% | +5.0% | -9.8% | -4.1% |
| 7D | -7.2% | +4.9% | -12.1% | -6.6% |
| 30D | +0.1% | +9.9% | -9.8% | +1.2% |
| 3M | +9.2% | +0.2% | +9.0% | +9.5% |
| 6M | +8.4% | +2.3% | +6.0% | +9.0% |
| YTD | +44.9% | +7.1% | +37.8% | +42.8% |
| 1Y | +49.9% | +13.1% | +36.7% | +47.0% |
| All | +49.9% | +14.9% | +34.9% | +47.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling